FRIDAY, March 6, 2026 (HealthDay News) -- Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.Muaaz Wajahath, from the Michigan State University College of Human Medicine in East Lansing, and colleagues evaluated the five-year risk for osteoporosis, gout, and osteomalacia in adults with both type 2 diabetes and obesity treated with GLP-1 RAs (semaglutide, liraglutide, dulaglutide, or exenatide) compared with matched controls (73,483 per group).The researchers found that at five years, patients exposed to GLP-1 RAs had a significantly increased risk for osteoporosis compared with controls (4.1 versus 3.2 percent
The approved Canadian indication is the reduction of excess visceral adipose tissue in treatment-experienced HIV-infected adult patients with lipodystrophy, with eligibility criteria including waist circumference thresholds and CT-confirmed visceral adipose tissue measurements
Advanced mitochondrial respiration assay for evaluation of mitochondrial dysfunction in Alzheimers disease
Persistent joint pain after weight loss may indicate underlying cartilage damage, structural issues, or other factors beyond weight
